Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea has entered into a contract partnership with Biomedical Advanced Research and Development Authority (BARDA), a division within the US Department of Health and Human Services, to develop BAL30072, Basilea's new monosulfactam antibiotic.
Subscribe to our email newsletter
BAL30072 is developed to treat severe infections, including nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria.
According to the terms of the contract, BARDA will provide nearly $17m of funding over the initial agreement period of 20 months.
Subsequent options, after a total six-year-period, would bring the total contract value of up to $89m under specific conditions.
Basilea CEO Ronald Scott said that BAL30072 is a potent, bactericidal antibiotic covering a broad range of clinically relevant multidrug-resistant Gram-negative bacteria.
The company has conducted a single ascending dose, double-blind, randomized, placebo-controlled trial and double-blind, randomized, placebo-controlled dose-ranging studies with multiple ascending doses in healthy volunteers to date.
Basilea chief medical officer Achim Kaufhold said that the drug has the potential of becoming an important treatment option for serious infections, including hospital-acquired infections due to resistant pathogens which are increasing in frequency.
"BAL30072 addresses the global concerns of antibiotic resistance and also has a potential role in biodefense, treating infections caused by potential biowarfare agents," Kaufhold added.